Prev：Pharmacological inhibition of the NLRP3 inflammasome as a potential target for cancer-induced bone pain(A21020-5)
Next：Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma(A25112-19.1005)
